Natco Pharma Approves Rights Issue Up to ₹1,300 Crore and Scheme Modifications
Natco Pharma Ltd · Outcome · 09 Sept 2026, 5:17 pm
Natco Pharma Approves Rights Issue Up to ₹1,300 Crore and Scheme Modifications Natco Pharma's Board approved a rights issue of equity shares (face value ₹2 each) aggregating up to ₹1,300 crore on 9th Sep'26, alongside approving the Draft Letter of Offer and forming a Fund-Raising Committee. The capital expansion will alter the company's shareholding pattern, prompting corresponding revisions to its demerger scheme with Natco Crop Health Sciences to maintain the proposed share swap ratio. Revised scheme filings will be submitted to stock exchanges following the completion of the rights issue prior to NCLT filing.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet · 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 · 14 Nov 2026
- Q2 FY27 Earnings Presentation · 13 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 · 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Outcome of Board Meeting · 13 Nov 2026
- Intimation of schedule of Concall · 13 Nov 2026
